Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer

Clinical Cancer Research

Volumn 6, Issue 10, 2000, Pages 3944-3948

  Passlick, Bernward ^a,b   Sienel, Wulf ^a,b   Seen Hibler, Rita ^a   Wockel, Werner ^b   Thetter, Olaf ^a,b   Mutschler, Wolf ^a   Pantel, Klaus ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PROGNOSIS; RECURRENCE; REGRESSION ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033760493     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Variation in survival of patients with lung cancer in Europe, 1985-1989
2. Cancer incidence and mortality, 1973-1995: A report card for the U. S.
3. Significant changes in the distribution of histologic types of lung cancer. A review of 4928 cases
4. 0 non-small cell lung cancer. Lung Cancer Study Group
5. Revisions in the International System for Staging Lung Cancer
6. Matrix metalloproteinases and metastasis
7. Progelatinase A activation during tumor cell invasion
8. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma
9. 72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells
10. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients
11. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
12. A new international staging system for lung cancer
13. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: Quantificative and morphological analyses
14. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia
15. Gelatinase A (MMP-2) and its mRNA detected in both neoplastic and stromal cells of tumors with different invasive and metastatic properties
16. Molecular regulation of cellular invasion - Role of gelatinase A and TIMP-2
17. MT-MMP expression and localisation in human lung and breast cancers
18. 3
19. Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma
20. Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane
21. Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors
22. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer
23. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma